Citigroup Maintains Neutral on Biogen, Raises Price Target to $215

Benzinga Newsdesk www.benzinga.com Neutral 49.8%

Neg 0% Neu 49.8% Pos 0%

Citigroup analyst Geoff Meacham maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $200 to $215.